X4 Pharmaceuticals (NASDAQ:XFOR) Now Covered by Leerink Partners

Equities researchers at Leerink Partners initiated coverage on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set an “outperform” rating and a $12.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 191.97% from the company’s current price.

XFOR has been the subject of several other research reports. Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.38.

X4 Pharmaceuticals Trading Down 4.6%

NASDAQ:XFOR opened at $4.11 on Tuesday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $4.83. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The firm has a market cap of $387.66 million, a P/E ratio of -0.91 and a beta of 0.31. The firm has a 50-day simple moving average of $4.13 and a 200-day simple moving average of $3.88.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The business had revenue of $2.71 million during the quarter, compared to analyst estimates of $3.20 million. Equities analysts anticipate that X4 Pharmaceuticals will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of XFOR. Bank of America Corp DE grew its position in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares during the last quarter. Rhumbline Advisers grew its position in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the last quarter. Jane Street Group LLC grew its position in X4 Pharmaceuticals by 112.5% during the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares during the last quarter. Vanguard Group Inc. grew its position in X4 Pharmaceuticals by 77.0% during the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares during the last quarter. Finally, Palumbo Wealth Management LLC purchased a new stake in X4 Pharmaceuticals during the 3rd quarter worth approximately $326,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.